3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Gels: new trials by email Literature Review of Gels trials Research Report on Gels
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo - Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ | Phase 2 | Terminated | Mayo Clinic | 65 | 2021-07-26 | 2026-09-24 |
| A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash ACZONE (dapsone) Gel, 5%, Vehicle Control - Rash, Non-small-Cell Lung Cancer | Phase 2 | Terminated | Allergan | 2 | 2006-06-01 | 2011-05-30 |
| Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis Bexarotene 1% gel - Parapsoriasis | Phase 2 | Terminated | Fox Chase Cancer Center | 8 | 2001-04-01 | 2013-04-16 |
Breast Carcinoma In Situ (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Exanthema (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Parapsoriasis (1)
Allergan (1) · Fox Chase Cancer Center (1) · Mayo Clinic (1)
United States (3)
Amy Degnim, M.D. (1) · Steven Garrett, MS, DDS (1) · Stuart R. Lessin, M.D. (1)
R01CA237607 (1)